Impact of sentinel lymph-node biopsy and FDG-PET in staging and radiation treatment of anal cancer patients.

Impact of sentinel lymph-node biopsy and FDG-PET in staging and radiation treatment of anal cancer patients. Sci Rep. 2020 Sep 03;10(1):14613 Authors: Slim N, Passoni P, Incerti E, Tummineri R, Gumina C, Cattaneo GM, De Nardi P, Canevari C, Fiorino C, Ronzoni M, Tamburini AM, Burgio V, Gianolli L, Di Muzio N Abstract To assess the role of sentinel lymph-node biopsy (SLNB) and FDG-PET in staging and radiation treatment (RT) of anal cancer patients. This retrospective study was performed on 80 patients (male: 32, female: 48) with a median age of 60 years (39-89 years) with anal squamous cell carcinoma who were treated from March 2008 to March 2018 at the IRCCS San Raffaele Hospital. Patients without clinical evidence of inguinal LNs metastases and/or with discordance between clinical evidence and imaging features were considered for SLNB. FDG-PET was performed in 69/80 patients. Patients with negative imaging in inguinal region and negative SLNB could avoid RT on groin to spare inguinal toxicity. CTV included GTV (primary tumour and positive LNs) and pelvic ± inguinal LNs. PTV1 and PTV2 corresponded to GTV and CTV, respectively, adding 0.5 cm. RT dose was 50.4 Gy/28 fractions to PTV2 and 64.8 Gy/36 fractions to PTV1, delivered with 3DCRT (n = 24) or IMRT (n = 56), concomitant to Mitomycin-C and 5-FU chemotherapy. FDG-PET showed inguinal uptake in 21/69 patients (30%) and was negative in 48/69 patients (70%). Lymphosci...
Source: Anal Sci - Category: Chemistry Authors: Tags: Sci Rep Source Type: research